CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
Who is this study for? Patients with central nervous system B-cell acute lymphocytic leukemia
What treatments are being studied? CD19 CAR-T cells
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Maximum Age: 60
Healthy Volunteers: f
View:
• Patients with CD19 positive central nervous system B-cell acute lymphocytic leukemia
• ALT/ AST 《 3x normal
• Creatinine 《 3x normal
• Age:10-60.
• Signed informed consent
Locations
Other Locations
China
The First Affiliated Hospital of Soochow University
RECRUITING
Suzhou
Contact Information
Primary
Sheng-Li Xue, MD
slxue@suda.edu.cn
86-13328008851
Backup
Lei Yu, Ph.D
ylyh188@163.com
86-13818629089
Time Frame
Start Date: 2017-03-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 10
Treatments
Experimental: Arm 1
CD19 CAR-T cells treated central nervous system B-cell acute lymphocytic leukemia.
Authors
Related Therapeutic Areas
Sponsors
Leads: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Collaborators: The First Affiliated Hospital of Soochow University